MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) in Patients With Unresectable Stage IV (Locally or Distantly Metastatic) Pancreatic Adenocarcinoma
Basic Trial Information
|Phase II||Treatment||Completed||18 and over||NCI||NCI-05-C-0141|
NCI-P6557, MDX-010-24, NCT00112580
Special Category: NCI Web site featured trial
Eligibility criteria include the following:
- At least 18 years old
- Measurable disease
- No previous MDX-010
- At least 3 weeks since chemotherapy or radiation therapy for pancreatic cancer
- More than 4 weeks since steroid therapy
- For more information about the eligibility criteria for this trial, refer to the Health Professional version.
Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Patients will receive a 1½ hour infusion of MDX-010 every 3 weeks for approximately 2 months. Treatment may repeat approximately every 3 months for up to two courses. Some patients may then receive up to 2 more courses of treatment .
Patients will be evaluated at 3 weeks, every 3 months for 1 year, every 6 months for 2 years, and once a year thereafter.
For more details about this trial, refer to the Health Professional version of the trial summary.
If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.
Trial Contact Information
Trial Lead Organizations
NCI - Center for Cancer Research
|Official Title||Phase II Trial of Single Agent Ipilimumab (MDX-010 anti CTLA-4) for Subjects with Locally Advanced or Metastatic Pancreatic Adenocarcinoma|
|Trial Start Date||2005-07-18|
|Trial Completion Date||2009-08-07|
|Registered in ClinicalTrials.gov||NCT00112580|
|Date Submitted to PDQ||2005-04-25|
|Information Last Verified||2009-08-26|